PRGO: Perrigo Company Aggregate Debts

Symbol and logo of brand Perrigo Company PLC (PRGO)

Pricing battles in the generics segment and regulatory inspections are creating pressure, which is confirmed by the debt capital volume; the value of 3.37 reflects this status. Perrigo Company plc (PRGO) bases its business growth on the acquisition of European brands and partnerships with pharmacies. Meanwhile, a pragmatic image and the trust of US retailers ensure the company maintains a stable position in the over-the-counter market.

Perrigo Company plc - PRGO Company Debts (period 07/04/2022 - 10/28/2026)

Analytical breakdowns and data insights for company Perrigo (PRGO)

- price and consensus price forecast:
Price Performance Chart Perrigo Corp|PRGO - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Perrigo Company|PRGO - Total Company Value
- book capitalization data:
Accounting Value of a Share Perrigo|PRGO - Company Book Value|Market Cap to Net Assets Ratio perrigo.com|PRGO - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Perrigo Company plc|PRGO - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Perrigo Company PLC|PRGO - Company Debts|Debts to Book Value Perrigo Company
Fundamental company valuation:PRGO (Perrigo Corp)
Original product of Perrigo Company PLC

This indicator aggregates all of the issuer's credit obligations, allowing for an assessment of business degradation risk through the balance of capital costs and expansion rates. An analysis of the total debt volume reveals the leverage stability of Perrigo Company plc (PRGO), whose role as a key generics supplier in the mature pharmacy retail sector requires strict control of the debt load to maintain operational stability.

Analysis of competing companies

Aggregate Debt Obligations Haleon Corp (HLN)|Company Aggregate Debts KVUE (Kenvue Inc.)|veronapharma.com - Company Aggregate Debts|Company Debts Jyong Biotech (MENS)|LGND: Aggregate Debt Obligations|AMRX (Amneal Pharmaceuticals Inc) - Company Debts|Alvotech Biopharmaceuticals (ALVO) - Company Total Debt|LQDA (Liquidia Corporation) - Company Aggregate Debts|Company Aggregate Debts glpg.com (GLPG)|ANI Pharmaceuticals, Inc. (ANIP) - Company Total Debt|Aggregate Debt Obligations MNKD (MannKind Corp)|AMPH: Company Debts|PCRX - Company Cumulative Debt|Company Total Debt ARS Pharmaceuticals SPRY|TBPH - Company Cumulative Indebtedness|Company Aggregate Debts Aquestive Therapeutics, Inc. AQST|scPharmaceuticals (SCPH) - Aggregate Debt Obligations|Company Aggregate Debts TECX (Tectonic Therapeutic Inc.)|Company Cumulative Debt TNXP|China SXT Pharmaceuticals (SXTC) - Company Debts|Aggregate Debt Obligations EPRX (eupraxiapharma.com)|BioHarvest Sciences Inc. (BHST) - Company Debts|Company Aggregate Indebtedness Invizyne Technologies EXOZ|ORMP (Oramed Pharma) - Company Aggregate Debts|ENTX: Company Cumulative Debt|Company Debts MindWalk Holdings HYFT|ABVC (abvcpharma.com) - Aggregate Debt Obligations|CPIX - Company Debts|Aggregate Debt Obligations Quantum BioPharma Ltd.|FGEN (FibroGen Corp) - Company Aggregate Debts|Company Total Debt Obligations Telomir Pharmaceuticals Corp (TELO)|RANI (Rani Therapeutics Holdings, Inc.) - Company Aggregate Debts|Synergy CHC Corp. - Company Total Indebtedness|RLYB (Rallybio Corp.) - Company Debts|Lexaria Bioscience (LEXX) - Company Cumulative Debt|Company Total Debt Pulmatrix Corp PULM|Pheton Holdings (PTHL) - Aggregate Debt Obligations|Company Aggregate Debts APM|Company Total Debt LYRA|Impact BioMedical - Company Debts|Company Cumulative Debt TNFA (tnfpharma.com)|cbdMD - Company Debts|PainReform Corp - Company Total Debt|Company Debts Auris Medical|LIPO - Company Aggregate Indebtedness|OPTN: Company Aggregate Debts|PIRS (Pieris Pharmaceuticals Inc) - Company Aggregate Debts|Company Debts Procaps Group SA (PROC)|Company Aggregate Debt Petros Pharma (PTPI)|Qilian International - Company Total Debt|Company Cumulative Debt acelyrin.com SLRN|Company Total Debt TFF Pharmaceuticals, Inc.